Free Trial

COMPASS Pathways (CMPS) Stock Price, News & Analysis

+0.02 (+0.27%)
(As of 05/24/2024 08:49 PM ET)
Today's Range
50-Day Range
52-Week Range
231,300 shs
Average Volume
618,783 shs
Market Capitalization
$511.48 million
P/E Ratio
Dividend Yield
Price Target

COMPASS Pathways MarketRank™ Stock Analysis

Analyst Rating
3.00 Rating Score
533.7% Upside
$47.40 Price Target
Short Interest
4.99% of Shares Sold Short
Dividend Strength
News Sentiment
1.43mentions of COMPASS Pathways in the last 14 days
Based on 2 Articles This Week
Insider Trading
Selling Shares
$903,450 Sold Last Quarter
Proj. Earnings Growth
From ($2.24) to ($2.17) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.91 out of 5 stars

Medical Sector

622nd out of 923 stocks

Pharmaceutical Preparations Industry

284th out of 429 stocks

CMPS stock logo

About COMPASS Pathways Stock (NASDAQ:CMPS)

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.

CMPS Stock Price History

CMPS Stock News Headlines

20 Most Depressed Countries in Asia
Compass Pathways co-founders step down from board
See More Headlines
Receive CMPS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for COMPASS Pathways and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Rating Score (0-4)
Research Coverage
5 Analysts


Net Income
Pretax Margin


Sales & Book Value

Annual Sales
Book Value
$3.79 per share


Free Float
Market Cap
$511.18 million

Social Links

20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

  • Mr. Kabir Kumar Nath M.A. (Age 60)
    M.B.A., CEO & Director
    Comp: $1.31M
  • Mr. Matthew Allen Owens (Age 47)
    General Counsel & Chief Legal Officer
    Comp: $684.51k
  • Dr. Guy Goodwin (Age 76)
    Chief Medical Officer
    Comp: $567k
  • Ms. Teri Loxam M.B.A. (Age 51)
    CFO, Principal Financial Officer & Principal Accounting Officer
  • Dr. Greg Ryslik Ph.D.
    Chief Technology Officer
  • Mr. Stephen D. Schultz
    Senior Vice President of Investor Relations
  • Mr. Christopher Williams
    Chief Communications Officer
  • Ms. Anne Benedict
    Chief People Officer
  • Mr. Lars Christian Wilde (Age 39)
    Senior Advisor
  • Mr. Trevor Mill
    Chief Development Officer

CMPS Stock Analysis - Frequently Asked Questions

Should I buy or sell COMPASS Pathways stock right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for COMPASS Pathways in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" CMPS shares.
View CMPS analyst ratings
or view top-rated stocks.

What is COMPASS Pathways' stock price target for 2024?

5 brokers have issued 1 year price targets for COMPASS Pathways' shares. Their CMPS share price targets range from $16.00 to $120.00. On average, they expect the company's share price to reach $47.40 in the next year. This suggests a possible upside of 533.7% from the stock's current price.
View analysts price targets for CMPS
or view top-rated stocks among Wall Street analysts.

How have CMPS shares performed in 2024?

COMPASS Pathways' stock was trading at $8.75 at the start of the year. Since then, CMPS stock has decreased by 14.5% and is now trading at $7.48.
View the best growth stocks for 2024 here

When is COMPASS Pathways' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 1st 2024.
View our CMPS earnings forecast

How were COMPASS Pathways' earnings last quarter?

COMPASS Pathways plc (NASDAQ:CMPS) announced its quarterly earnings results on Thursday, February, 29th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.37) by $0.16.

What ETFs hold COMPASS Pathways' stock?

ETFs with the largest weight of COMPASS Pathways (NASDAQ:CMPS) stock in their portfolio include AdvisorShares Psychedelics ETF (PSIL), Subversive Mental Health ETF (SANE) and ARK Genomic Revolution ETF (ARKG).Grizzle Growth ETF (DARP).

What other stocks do shareholders of COMPASS Pathways own?

Based on aggregate information from My MarketBeat watchlists, some companies that other COMPASS Pathways investors own include Nikola (NKLA), Vaxart (VXRT), Beyond Meat (BYND), Evofem Biosciences (EVFM), GrowGeneration (GRWG), McDonald's (MCD), Plug Power (PLUG), Block (SQ), Workhorse Group (WKHS) and

When did COMPASS Pathways IPO?

COMPASS Pathways (CMPS) raised $100 million in an IPO on Friday, September 18th 2020. The company issued 6,700,000 shares at $14.00-$16.00 per share. Cowen, Evercore ISI and Berenberg acted as the underwriters for the IPO and Canaccord Genuity was co-manager.

Who are COMPASS Pathways' major shareholders?

COMPASS Pathways' stock is owned by many different institutional and retail investors. Top institutional shareholders include Affinity Asset Advisors LLC (1.50%), RA Capital Management L.P. (1.16%), Rosalind Advisors Inc. (1.19%), Sumitomo Mitsui Trust Holdings Inc. (0.53%), Nikko Asset Management Americas Inc. (0.53%) and SVB Wealth LLC (0.08%). Insiders that own company stock include David Y Norton, Ekaterina Malievskaia and George Jay Goldsmith.
View institutional ownership trends

How do I buy shares of COMPASS Pathways?

Shares of CMPS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CMPS) was last updated on 5/27/2024 by Staff

From Our Partners